Adrenomyeloneuropathy Gene Therapy Trial Begins
The trial will incorporate findings from CYGNET, a natural history study designed to assess the disease progression of AMN.
SwanBio Therapeutics has announced the initiation of the phase 1/2 PROPEL clinical trial (NCT05394064) for SBT101, an investigational gene therapy intended to treat adrenomyeloneuropathy (AMN).1
SBT101 is intended to deliver a functional copy of the human adenosine triphosphate (ATP)-binding cassette transporter subfamily D member 1 gene (hABCD1) via a recombinant adeno-associated virus serotype 9 (AAV9) vector. The multinational, randomized, blinded, dose-escalation PROPEL study will evaluate the safety and efficacy of the therapy for male patients aged 18 to 65 who have been diagnosed with X-linked adrenoleukodystrophy (ALD) with a confirmed mutation in the ABCD1 gene.
The trial will incorporate findings from
“As we wrap up a pivotal year for SwanBio, I am pleased to announce that we have successfully initiated PROPEL, our first interventional clinical study,” Tom Anderson, chief executive officer and director, SwanBio, said in a statement.1 “This milestone comes on the heels of completing enrollment and over-subscribing our natural history study, CYGNET. These 2 achievements not only demonstrate Swan’s ongoing commitment to the AMN community, but also highlight the exceptional creativity and execution capabilities of our team. We expect to dose the first patient in PROPEL in early 2023 and are well positioned to meet our recruitment goals for this trial.”
The investigational new drug application for SBT101
REFERENCES
1. Swanbio Therapeutics initiates first-in-human study of AAV gene therapy for adrenomyeloneuropathy. News release. SwanBio Therapeutics. December 15, 2022. https://swanbiotx.com/investors-and-media/swanbio-therapeutics-initiates-first-in-human-study-of-aav-gene-therapy-for-adrenomyeloneuropathy/
2. SwanBio presents design of innovative natural history study aimed to evolve understanding of adrenomyeloneuropathy and inform future treatments. News release. SwanBio Therapeutics. June 27, 2022. https://swanbiotx.com/investors-and-media/swanbio-presents-design-of-innovative-natural-history-study-aimed-to-evolve-understanding-of-adrenomyeloneuropathy-and-inform-future-treatments/
3. SwanBio Therapeutics Announces FDA investigational new drug clearance for first AAV-based gene therapy for the treatment of adrenomyeloneuropathy. News release. SwanBio Therapeutics. January 25, 2022. https://www.businesswire.com/news/home/20220125005388/en/SwanBio-Therapeutics-Announces-FDA-Investigational-New-Drug-Clearance-for-First-AAV-Based-Gene-Therapy-for-the-Treatment-of-Adrenomyeloneuropathy
4. SwanBio Therapeutics announces new preclinical data demonstrating proof of principle for SBT101 gene therapy as a potential treatment of adrenomyeloneuropathy. News release. SwanBio Therapeutics. October 19, 2021. https://swanbiotx.com/investors-and-media/swanbio-therapeutics-announces-new-preclinical-data-demonstrating-proof-of-principle-for-sbt101-gene-therapy-as-a-potential-treatment-of-adrenomyeloneuropathy/
5. Updated preclinical data supportpotential of first AAV-based gene therapy as a treatment for adrenomyeloneuropathy. News release. SwanBio Therapeutics. April 5, 2022. https://swanbiotx.com/investors-and-media/updated-preclinical-data-support-potential-of-first-aav-based-gene-therapy-as-a-treatment-for-adrenomyeloneuropathy/
6. FDA grants fast track designation to SBT101, the first investigational AAV-based gene therapy for patients with adrenomyeloneuropathy (AMN). News release. SwanBio. February 16, 2022. https://www.businesswire.com/news/home/20220216005313/en/FDA-Grants-Fast-Track-Designation-to-SBT101-the-First-Investigational-AAV-Based-Gene-Therapy-for-Patients-With-Adrenomyeloneuropathy-AMN
7. FDA grants orphan drug designation to SBT101, the first investigational AAV-based gene therapy for adrenomyeloneuropathy (AMN). News release. SwanBio Therapeutics. March 15, 2022. https://www.biospace.com/article/releases/fda-grants-orphan-drug-designation-to-sbt101-the-first-investigational-aav-based-gene-therapy-for-adrenomyeloneuropathy-amn-/
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025